Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded down 7.8% during mid-day trading on Tuesday . The company traded as low as $12.68 and last traded at $12.72. 2,106,747 shares changed hands during mid-day trading, an increase of 57% from the average session volume of 1,341,836 shares. The stock had previously closed at $13.80.
A number of analysts recently issued reports on the company. BidaskClub downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th. Wells Fargo & Co set a $23.00 target price on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 8th. BTIG Research set a $17.00 price target on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 7th. Mizuho cut their price target on Ironwood Pharmaceuticals to $15.00 and set a “buy” rating on the stock in a research note on Monday, November 19th. Finally, HC Wainwright set a $13.00 price target on Ironwood Pharmaceuticals and gave the company a “sell” rating in a research note on Wednesday, October 31st. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. Ironwood Pharmaceuticals presently has an average rating of “Hold” and an average price target of $16.45.
The company has a market cap of $2.13 billion, a P/E ratio of -13.68 and a beta of 1.27.
In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 116,651 shares of Ironwood Pharmaceuticals stock in a transaction dated Friday, October 5th. The stock was sold at an average price of $17.53, for a total value of $2,044,892.03. Following the transaction, the insider now owns 70,680 shares in the company, valued at $1,239,020.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.63% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC grew its stake in Ironwood Pharmaceuticals by 3.1% in the second quarter. FMR LLC now owns 18,088,500 shares of the biotechnology company’s stock valued at $345,852,000 after purchasing an additional 547,724 shares during the last quarter. Vanguard Group Inc. grew its stake in Ironwood Pharmaceuticals by 3.2% in the third quarter. Vanguard Group Inc. now owns 12,324,954 shares of the biotechnology company’s stock valued at $227,518,000 after purchasing an additional 377,177 shares during the last quarter. OppenheimerFunds Inc. grew its stake in Ironwood Pharmaceuticals by 11.1% in the second quarter. OppenheimerFunds Inc. now owns 2,872,640 shares of the biotechnology company’s stock valued at $54,925,000 after purchasing an additional 286,590 shares during the last quarter. Northern Trust Corp grew its stake in Ironwood Pharmaceuticals by 5.1% in the second quarter. Northern Trust Corp now owns 1,641,866 shares of the biotechnology company’s stock valued at $31,392,000 after purchasing an additional 80,100 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Ironwood Pharmaceuticals by 1,569.4% in the second quarter. Point72 Asset Management L.P. now owns 1,085,106 shares of the biotechnology company’s stock valued at $20,747,000 after purchasing an additional 1,020,106 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.themarketsdaily.com/2018/12/05/ironwood-pharmaceuticals-irwd-stock-price-down-7-8.html.
Ironwood Pharmaceuticals Company Profile (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.
Read More: The risks of owning bonds
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.